Notizie AIOM – anno XIV n. 602
FDA Approves Pembrolizumab for Frontline PD-L1+ NSCLC
The FDA has approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations. ...Leggi tutto
Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening
Since the US Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening, there have been conflicting reports regarding the impact on the behavior of providers. This study analyzed real-world data on PSA ordering and referral practices ...Leggi tutto
EC Approves Liposomal Irinotecan for Pancreatic Cancer
The European Commission (EC) has approved pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy. The approval was based on ...Leggi tutto
20 ottobre 2016 – AIFA: online il bando 2016 per la ricerca indipendente
Leggi tuttoAre Liquid Biopsies Ready for Prime Time of Clinical Applications
Molecular targeted therapy represented by EGFR tyrosine kinase inhibitors (TKIs) based on genotyping has become a paradigm for precision management of NSCLC. To realize detection and monitoring of EGFR activating and resistance mutations during EGFR TKI therapy, it is important ...Leggi tutto